Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Schering-Plough, Merck Will Have Better Reach And Larger Product Basket In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After a long spell of near-dormancy, in Dec. 2006, Schering-Plough's India unit roped in K.G. Ananthakrishnan from Pfizer India to head its fledgling arm with a mandate to revive the company

You may also be interested in...



Merck Unites With Schering Plough But India Goes Slow On Integration; Operational Structure And Merger Issues Remain Foggy

MUMBAI - It may have been a mega integration of operations of the two New Jersey-headquartered companies - Merck and Schering Plough - but it stays status quo in India and the affiliates of the two large companies will continue to operate independently till the final contours emerge "in the next few months.

Merck Unites With Schering Plough But India Goes Slow On Integration; Operational Structure And Merger Issues Remain Foggy

MUMBAI - It may have been a mega integration of operations of the two New Jersey-headquartered companies - Merck and Schering Plough - but it stays status quo in India and the affiliates of the two large companies will continue to operate independently till the final contours emerge "in the next few months.

Emerging Market Outlook: PharmAsia News Earnings Call Roundup

In a new feature, PharmAsia News takes a look at the earnings calls for some of the major pharma companies and what they are saying about Asia Pacific and emerging markets

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel